胰腺导管腺癌化疗反应评估:弥散加权MR定量参数与RECIST的比较
前瞻性纳入24例胰腺导管腺癌患者,于化疗前、第2周和第8周行弥散加权MR检查,比较ADC及直方图衍生参数与RECIST 1.1评估化疗反应。15/24例为反应者,RECIST 1.1在第8周仅正确识别6/15例反应者;第8周DW-volume相对变化正确分类22/24例患者(P < .0001)。结论认为ROI-ADC、DW-volume和直方图衍生弥散参数较RECIST 1.1更准确区分化疗反应者与非反应者。
要点
- RECIST 1.1在第8周仅正确识别6/15例反应者,基于直径的疗效评估可能低估胰腺导管腺癌化疗反应。
- 第8周DW-volume相对变化正确分类22/24例患者(P < .0001),为分类准确性最高的参数。
- 第2周25百分位H-D和H-PF相对变化正确分类20/24例患者(P = .003),提示早期变化可辅助分类。
核心结论
- ROI-ADC、DW-volume和直方图衍生弥散参数较RECIST 1.1更准确区分接受化疗的胰腺导管腺癌反应者与非反应者。
研究设计与样本
- 前瞻性研究,纳入24例胰腺导管腺癌患者,于化疗开始前、第2周和第8周行弥散加权MR检查。
- 肿瘤直径在T2加权图像上测量;在ADC图上勾画感兴趣区获得ROI-ADC;基于b = 1000 s/mm2图像进行容积分割获得DW-volume及直方图衍生弥散参数(H-ADC、H-D和H-PF)。
- 所有变量及其相对变化与基线比较或用于反应者与非反应者间比较,并进行判别分析。
关键影像表现/征象
- 第2周反应者DW-volume降低(P = .002),ROI-ADC均值、H-D均值升高(P = .047;P = .048)。
- 第2周H-D第25百分位在反应者升高、在非反应者降低(P = .016;P = .048)。
- 第8周反应者DW-volume降低,ROI-ADC均值及H-ADC、H-D的第25、50、75百分位升高(P < .05)。
- 非反应者各时间点上述参数均无变化(P > .05)。
诊断标准与关键数值
- RECIST 1.1在第8周正确识别6/15例反应者。
- 第2周H-D第25百分位和H-PF相对变化正确分类20/24例患者(P = .003)。
- 第8周DW-volume相对变化正确分类22/24例患者(P < .0001)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To prospectively assess chemotherapy-induced changes in pancreatic ductal adenocarcinoma (PDA) with diffusion-weighted (DW)-MR quantitative metrics, including apparent diffusion coefficient (ADC) and histogram-derived parameters, compared with RECIST 1.1.
METHODS: 24 patients underwent DW-MR at baseline, week-2 and week-8 after chemotherapy initiation. Tumour diameter was assessed on T2-weighted images. Regions-of-interest (ROI) were drawn on ADC map for ROI-ADC. Volume segmentation (b = 1000 s/mm2 images) provided DW-volume and histogram-derived diffusion parameters (H-ADC, H-D and H-PF). All variables and their relative change were compared to baseline or between responders and non-responders. Discriminant analysis was performed.
RESULTS: 15/24 patients were responders. RECIST 1.1 correctly characterized 6/15 responders at week-8. At week-2, in responders DW-volume decreased (P = .002); ROI-ADC mean H-D increased (P = .047; P = .048;). The 25th percentile H-D increased in responders and decreased in non-responders (P = .016; P = .048). At week-8 in responders DW-volume decreased and ROI-ADC mean, 25th, 50th, 75th percentiles of H-ADC and H-D increased (P < .05). No changes were observed in non-responders (P > .05). At week-2, 25th percentile of H-D and H-PF relative change correctly classified 20/24 patients (P = .003); at week-8, DW-volume relative change correctly classified 22/24 patients (P < .0001).
CONCLUSIONS: ROI-ADC, DW-volume and histogram-derived diffusion parameters are more accurate to categorize responding and non-responding PDA patients treated with chemotherapy compared with RECIST 1.1.
引用
- Bali MA, Pullini S, Metens T, et al. Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. Eur J Radiol. 2018. PMID: 29857866. doi:10.1016/j.ejrad.2018.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。